JOURNAL OF PHARMA INSIGHTS AND RESEARCH ISSN NO. 3048-5428

REVIEW ARTICLE

Molecular Virology, Pathogenesis, and Clinical Management of Human Metapneumovirus

Purnima Gedela[1], Harika Kasi[1], Abhishek Ch[1], Vyshnavi Ramya Tumu[1], Venkateswarlu Gubbala[1], Anitha Anasuri*[2]

[1] *UG Scholar, Department of Pharmaceutical Analysis and QA, Koringa College of Pharmacy, Korangi, Tallarevu, Andhra Pradesh, India*
[2] *Assistant Professor, Department of Pharmaceutical Analysis and QA, Koringa College of Pharmacy, Korangi, Tallarevu, Andhra Pradesh, India*

Publication history: Received on 5th July 2025; Revised on 12th Aug 2025; Accepted on 21st August 2025

Article DOI: 10.69613/26fsz770

Abstract: Human metapneumovirus (hMPV), first isolated in 2001 in the Netherlands, has emerged as a significant respiratory pathogen with global health implications. This paramyxovirus, classified within the Pneumoviridae family, shows remarkable genetic and antigenic diversity through its two major genetic lineages (A and B) and their corresponding subtypes (A1, A2a, A2b, B1, and B2). The virus causes a spectrum of respiratory illnesses, ranging from mild upper respiratory tract infections to severe bronchiolitis, pneumonia, and exacerbation of chronic respiratory conditions. Clinical manifestations often mirror those of respiratory syncytial virus (RSV) infections, presenting diagnostic challenges in clinical settings. The pathogenesis involves direct viral cytopathic effects and immunopathological responses, with the fusion (F) and attachment (G) glycoproteins playing crucial roles in viral entry and host immune response modulation. The virus spreads primarily through respiratory droplets and fomites, with an incubation period of 3-6 days. While hMPV infections occur across all age groups, severe disease manifestations predominantly affect young children (<5 years), older adults (>65 years), and immunocompromised individuals. Recent data suggest that hMPV accounts for 5-15% of hospitalizations due to respiratory tract infections in these vulnerable populations. Current diagnostic methods include reverse transcription polymerase chain reaction (RT-PCR), multiplex PCR panels, and rapid antigen detection tests, each offering different advantages in terms of sensitivity, specificity, and turnaround time. Treatment remains primarily supportive, focusing on symptom management and respiratory support when necessary.

Keywords: Human Metapneumovirus; Respiratory Infections; Viral Pathogenesis; Molecular Diagnostics; Antiviral Therapeutics

1. Introduction

Human metapneumovirus (hMPV), first isolated in 2001 from respiratory specimens of young children in the Netherlands, represents a significant advancement in our understanding of viral respiratory pathogens [1]. The virus belongs to the Pneumoviridae family, a classification revised in 2016 based on detailed genomic and structural analyses [2]. As a negative-sense, single-stranded RNA virus, hMPV possesses a genome approximately 13 kilobases in length, encoding eight genes that produce nine essential proteins [3]. The virus's genome organization reveals remarkable similarities to respiratory syncytial virus (RSV), though hMPV lacks the non-structural proteins NS1 and NS2, which may explain distinct variations in host immune responses [4]. The viral genome encodes several crucial proteins: nucleoprotein (N), phosphoprotein (P), matrix protein (M), fusion protein (F), small hydrophobic protein (SH), glycoprotein (G), large polymerase (L), and two matrix-2 proteins (M2-1 and M2-2) [5].



Figure 1. Structure of Human Meta Pneumovirus (hMPV)

---

[*] Corresponding author: Anitha Anasuri

Genetic analyses have identified two primary lineages, A and B, each further subdivided into A1, A2, B1, and B2 subgroups [6]. These distinct genetic variants exhibit temporal and geographical distribution patterns, contributing to the virus's evolutionary dynamics and potential for reinfection [7]. The discovery of hMPV filled a crucial gap in our understanding of respiratory infections, as retrospective studies revealed its presence in archived specimens dating back to the 1950s [8]. The global impact of hMPV became apparent through extensive epidemiological studies, demonstrating its presence in approximately 4-16% of acute respiratory infections [9]. The virus shows a distinct seasonal pattern in temperate climates, typically coinciding with or following RSV seasons, while tropical regions may experience different temporal distributions [10].

2. Molecular Virology

2.1. Viral Structure

The hMPV virion exhibits a pleomorphic morphology, ranging from spherical to filamentous forms, with dimensions varying from 150 to 600 nanometers [11]. The virus's structural organization follows the typical pattern of pneumoviruses, with a lipid envelope containing three surface glycoproteins: fusion (F), attachment (G), and small hydrophobic (SH) proteins [12].

2.2. Genome Organization

The viral genome's organization reflects evolutionary adaptations for efficient replication and transmission. The nucleoprotein (N) forms a helical nucleocapsid complex with viral RNA, providing protection against cellular nucleases [13]. The phosphoprotein (P) serves as an essential cofactor for the viral RNA-dependent RNA polymerase (L protein), facilitating efficient genome replication [14].

2.3. Viral Entry and Replication

The infection cycle begins with viral attachment to host cells through interactions between the G protein and cellular glycosaminoglycans, particularly heparan sulfate [15]. The F protein then mediates membrane fusion, allowing viral contents to enter the cytoplasm. Within the cell, the viral RNA-dependent RNA polymerase complex initiates transcription of viral genes in a sequential manner, following the conserved gradient of gene expression characteristic of negative-strand RNA viruses [16].

3. Epidemiology

Human metapneumovirus shows distinct seasonal patterns that vary by geographical location and climate. In temperate regions, peak infection rates typically occur during late winter and early spring, often following or overlapping with RSV seasons [17]. Surveillance data from 2014-2024 indicates shifting seasonal patterns post-pandemic, with altered timing of peak incidence and modified co-circulation patterns with other respiratory viruses [18].

The highest infection rates occur in young children, particularly those aged 6 months to 4 years, with seroprevalence studies indicating that nearly all children encounter hMPV by age 5 [19]. In 2019, epidemiological studies documented approximately 473,000 hospitalizations related to hMPV in older adults globally, with higher positivity rates observed in high-income countries [20]. The virus demonstrates a bimodal age distribution of severe disease, affecting both young children and elderly adults most significantly [21]. Regional differences in hMPV prevalence and genetic diversity have been documented worldwide. Studies from Asia indicate prevalence rates of 4-12% among patients with acute respiratory infections, while European surveillance data suggests rates of 7-15% [22]. In tropical and subtropical regions, viral activity often correlates with rainfall patterns and humidity levels, leading to less distinct seasonal boundaries [23].

Table 1. Clinical and Epidemiological Characteristics of hMPV Infections by Age Group (2020-2024)

Age Group	Prevalence Rate (%)	Common Presentations	Hospitalization Rate (%)	Mortality Rate (%)
0-2 years	15-20	Bronchiolitis, Pneumonia	8-12	0.1-0.3
2-5 years	10-15	URTI, Wheezing	5-8	0.05-0.1
5-18 years	5-8	URTI, Bronchitis	2-4	<0.05
18-65 years	3-6	URTI, Bronchitis	1-3	0.1-0.2
65 years	8-12	Pneumonia, COPD	10-15	0.5-1.0

4. Transmission and Pathogenesis

4.1. Transmission Mechanisms

4.1.1. Primary Routes

The virus primarily spreads through respiratory droplets and close contact with infected individuals. Viral particles can remain viable on environmental surfaces for several hours, facilitating indirect transmission through fomites [24]. The incubation period typically ranges from 3-6 days, with viral shedding continuing for 1-2 weeks in immunocompetent hosts [25].

4.1.2. Environmental Factors

Temperature and humidity significantly influence viral stability and transmission efficiency. Studies indicate enhanced viral survival in conditions of lower temperature and moderate humidity, partially explaining seasonal infection patterns [26].

4.2. Pathogenic Mechanisms

4.2.1. Cellular Entry and Replication

Upon entering the respiratory tract, hMPV primarily targets ciliated epithelial cells. The viral F protein mediates membrane fusion, while the G protein facilitates initial attachment to host cell surface molecules [27]. Following entry, viral replication occurs in the cytoplasm, with new virions assembling at the plasma membrane [28].

4.2.2. Host Immune Response

The host immune response to hMPV infection involves both innate and adaptive components. Initial recognition occurs through pattern recognition receptors, including TLR4 and RIG-I, triggering production of type I interferons and proinflammatory cytokines [29]. The adaptive immune response generates virus-specific antibodies and T cells, though immunity appears to be incomplete and temporary, allowing reinfection [30]

Table 2. Environmental Stability of hMPV Under Different Conditions

Condition	Survival Time	Infectivity Rate (%)	Prevention Strategy
Room temperature (20-25°C)	4-8 hours	40-60	Regular surface disinfection
Low temperature (4°C)	24-48 hours	70-80	Cold chain maintenance
High humidity (>80%)	2-4 hours	30-50	Humidity control
Dry conditions (<30%)	8-12 hours	50-70	Environmental monitoring
Direct sunlight	1-2 hours	10-20	UV protection
Fomites (plastic/metal)	6-12 hours	40-60	Surface cleaning protocols

5. Clinical Manifestations

5.1. Clinical Spectrum of Disease

The clinical presentation of hMPV infection varies significantly, ranging from mild upper respiratory symptoms to severe lower respiratory tract disease. Upper respiratory manifestations include rhinorrhea, cough, and pharyngitis, while lower respiratory involvement presents as bronchiolitis, pneumonia, or exacerbation of underlying respiratory conditions [31]. The severity of symptoms correlates strongly with host factors, including age, immune status, and presence of comorbidities [32].

5.2. Age-Specific Presentations

5.2.1. Pediatric Manifestations

In children, hMPV frequently causes bronchiolitis characterized by wheezing, tachypnea, and hypoxemia. Studies indicate that 5-15% of hospitalized children with bronchiolitis test positive for hMPV [33]. Fever occurs in approximately 50-75% of pediatric cases, often accompanied by decreased appetite and lethargy [34].

5.2.2. Adult Presentations

Adults typically experience milder symptoms, though elderly individuals and those with compromised immunity may develop severe disease. Common manifestations include prolonged cough, sputum production, and dyspnea [35]. In patients with chronic obstructive pulmonary disease (COPD), hMPV infection frequently triggers acute exacerbations [36].

5.3. Complications

Severe complications predominantly affect high-risk populations. Acute respiratory distress syndrome (ARDS) develops in approximately 2-5% of hospitalized cases, particularly in immunocompromised patients [37]. Secondary bacterial infections occur in 15-20% of severe cases, most commonly involving Streptococcus pneumoniae and Haemophilus influenzae [38]. Extrapulmonary manifestations, though rare, include myocarditis, encephalitis, and hepatitis [39].

6. Diagnosis

6.1. Molecular Diagnostic Methods

6.1.1. Reverse Transcription PCR

RT-PCR represents the gold standard for hMPV detection, offering high sensitivity and specificity. Real-time RT-PCR assays can detect viral loads as low as 10-100 copies per milliliter of respiratory specimen [40]. Multiplex PCR platforms enable simultaneous detection of hMPV alongside other respiratory pathogens, enhancing diagnostic efficiency [41].



Figure 2. Diagnostic Algorithm for hMPV

6.1.2. Next-Generation Sequencing

Advanced sequencing technologies facilitate detailed genetic characterization and surveillance of viral strains. These methods have revealed emerging variants and aided in understanding viral evolution patterns [42].

6.2. Serological Testing

Enzyme-linked immunosorbent assays (ELISA) detect virus-specific IgG and IgM antibodies, primarily useful for epidemiological studies and retrospective diagnosis [43]. Neutralization assays provide information about protective immunity but require specialized laboratory facilities [44].

6.3. Culture-Based Methods

Although less frequently used for routine diagnosis, viral culture in specific cell lines remains valuable for research purposes and characterization of new viral strains. LLC-MK2 and Vero cells support hMPV growth, showing characteristic cytopathic effects after 10-14 days [45].

Table 3. Comparison of Diagnostic Methods for hMPV Detection

Method	Sensitivity (%)	Specificity (%)	Turnaround Time	Cost Level	Main Advantages
RT-PCR	95-99	98-100	2-4 hrs	High	Gold standard
Rapid Antigen Testing	70-85	90-95	15-30 min	Low	Quick results
Cell Culture	60-80	100	7-14 days	Medium	Virus isolation
Serology (IgG/IgM)	80-90	85-95	1-2 days	Medium	Retrospect. diagnosis
Multiplex PCR	90-95	95-98	2-6 hrs	High	Multiple pathogens

7. Therapeutic Management

7.1. Supportive Care

Current management of hMPV infections primarily focuses on supportive measures. Mild cases typically resolve with adequate hydration, rest, and antipyretics [46]. For moderate to severe cases, oxygen supplementation maintains appropriate saturation levels, with targets above 92% in previously healthy individuals and 88-92% in those with chronic respiratory conditions [47].



Figure 3. Treatment of hMPV

7.2. Advanced Respiratory Support

Severe cases may require intensive care intervention. High-flow nasal cannula (HFNF) therapy has shown efficacy in managing respiratory distress, reducing the need for mechanical ventilation in 60-70% of cases [48]. For patients requiring mechanical ventilation, lung-protective strategies with low tidal volumes (4-6 mL/kg) and appropriate positive end-expiratory pressure (PEEP) optimize outcomes [49].

7.3. Antiviral Drugs

Ribavirin, a broad-spectrum antiviral agent, demonstrates in vitro activity against hMPV, though clinical evidence supporting its use remains limited [50]. In immunocompromised patients, combination therapy with intravenous immunoglobulin (IVIG) and ribavirin has shown potential benefit in small observational studies [51].

Novel antiviral compounds targeting the viral fusion protein show promise in preclinical studies. Small molecule inhibitors and peptide-based fusion inhibitors have demonstrated efficacy in animal models [52]. Additionally, broadly neutralizing monoclonal antibodies targeting conserved epitopes of the F protein represent a potential therapeutic strategy [53].

8. Prevention And Control

8.1. Infection Control

Implementation of standard and droplet precautions effectively reduces transmission in healthcare settings. These measures include proper hand hygiene, use of personal protective equipment, and appropriate patient isolation [54]. Environmental cleaning with virucidal agents inactivates hMPV on surfaces, though the virus shows variable environmental stability depending on conditions [55].

8.2. Development of Vaccine

Multiple vaccine platforms are under investigation, including live-attenuated, subunit, and vector-based approaches. Live-attenuated vaccine candidates, generated through reverse genetics, show promising immunogenicity profiles in preclinical studies [56]. The development of stabilized prefusion F protein immunogens has enhanced vaccine design strategies [57].

The main challenges in vaccine development include achieving broad protection against multiple viral strains and maintaining long-term immunity. Novel approaches, such as mRNA-based vaccines and virus-like particles, offer potential solutions to these challenges [58].

Table 4. Vaccine Development Status

Vaccine Type	Platform Technology	Development Stage	Immune Response	Challenges
Live Attenuated	Classical attenuation	Phase II	Broad cellular & humoral	Safety in infants
Subunit	F protein based	Phase I/II	Mainly humoral	Adjuvant selection
Vector-based	Adenovirus	Preclinical	Balanced response	Pre-existing immunity
mRNA	Lipid nanoparticle	Phase I	Strong humoral	Storage requirements
VLP	Protein assembly	Preclinical	Balanced response	Manufacturing complexity

9. Current Research

Recent advances in structural biology have revealed detailed mechanisms of viral entry and fusion. Cryo-electron microscopy studies of the F protein in its pre- and post-fusion conformations guide rational drug design [59]. Host-pathogen interaction studies identify cellular factors essential for viral replication, potentially offering new therapeutic targets [60]. Recent drug discovery efforts focus on targeting conserved viral proteins. Structure-guided design of fusion inhibitors has yielded compounds with nanomolar potency against multiple hMPV strains [61]. Novel therapeutic approaches include development of small interfering RNAs (siRNAs) targeting essential viral genes and peptide-based entry inhibitors [62].

Investigation of host immune responses has identified potential immunomodulatory interventions. Targeting specific inflammatory pathways, particularly those involving IL-6 and TNF-α, may reduce disease severity in severe cases [63]. Development of therapeutic antibodies targeting both viral proteins and host immune factors represents a promising approach [64]. Emerging diagnostic platforms incorporate CRISPR-based detection methods, offering rapid and sensitive viral detection. These systems demonstrate sensitivity comparable to RT-PCR while providing results in under 30 minutes [65]. The combination of artificial intelligence algorithms with molecular diagnostics improves accuracy and prediction of disease severity [66].

10. Conclusion

Human metapneumovirus is a major respiratory pathogen, with diverse epidemiological patterns and clinical significance across different population groups. Recent molecular and diagnostic studies have significantly improved our ability to detect and characterize hMPV infections, enabling more timely and accurate patient care. While current management primarily centers on supportive measures, several promising therapeutic candidates are in development. The main priorities for this pathogen of concern are to develop effective antiviral treatments, particularly for severe cases in high-risk populations, development of vaccine candidates through clinical trials, with special attention to cross-protection against multiple viral strains and implementation of standardized molecular surveillance systems for better tracking of viral evolution and emergence of new variants.

References

[1] van den Hoogen BG, de Jong JC, Groen J, Kuiken T, de Groot R, Fouchier RA, et al. A newly discovered human pneumovirus isolated from young children with respiratory tract disease. Nat Med. 2001;7(6):719-24.

[2] Rima B, Collins P, Easton A, Fouchier R, Kurath G, Lamb RA, et al. ICTV Virus Taxonomy Profile: Pneumoviridae. J Gen Virol. 2017;98(12):2912-3.

[3] Edwards KM, Zhu Y, Griffin MR, Weinberg GA, Hall CB, Szilagyi PG, et al. Burden of human metapneumovirus infection in young children. N Engl J Med. 2013;368(7):633-43.

[4] Schuster JE, Williams JV. Human metapneumovirus. Pediatr Rev. 2013;34(12):558-65.

[5] Panda S, Mohakud NK, Pena L, Kumar S. Human metapneumovirus: review of an important respiratory pathogen. Int J Infect Dis. 2014;25:45-52.

[6] Kahn JS. Human metapneumovirus: a newly emerging respiratory pathogen. Curr Opin Infect Dis. 2006;19(3):277-81.

[7] Hamelin ME, Abed Y, Boivin G. Human metapneumovirus: a new player among respiratory viruses. Clin Infect Dis. 2004;38(7):983-90.

[8] Williams JV, Harris PA, Tollefson SJ, Halburnt-Rush LL, Pingsterhaus JM, Edwards KM, et al. Human metapneumovirus and lower respiratory tract disease in otherwise healthy infants and children. N Engl J Med. 2004;350(5):443-50.

[9] van den Hoogen BG, Bestebroer TM, Osterhaus AD, Fouchier RA. Analysis of the genomic sequence of a human metapneumovirus. Virology. 2002;295(1):119-32.

[10] Boivin G, De Serres G, Côté S, Gilca R, Abed Y, Rochette L, et al. Human metapneumovirus infections in hospitalized children. Emerg Infect Dis. 2003;9(6):634-40.

[11] Falsey AR, Erdman D, Anderson LJ, Walsh EE. Human metapneumovirus infections in young and elderly adults. J Infect Dis. 2003;187(5):785-90.

[12] Céspedes PF, Palavecino CE, Kalergis AM, Bueno SM. Modulation of host immunity by the human metapneumovirus. Clin Microbiol Rev. 2016;29(4):795-818.

[13] Ren J, Phan T, Bao X. Recent vaccine development for human metapneumovirus. J Gen Virol. 2015;96(7):1515-20.

[14] Schildgen V, van den Hoogen B, Fouchier R, Tripp RA, Alvarez R, Manoha C, et al. Human metapneumovirus: lessons learned over the first decade. Clin Microbiol Rev. 2011;24(4):734-54.

[15] Heininger U, Kruker AT, Bonhoeffer J, Schaad UB. Human metapneumovirus infections-biannual epidemics and clinical findings in children in the region of Basel, Switzerland. Eur J Pediatr. 2009;168(12):1455-60..

[16] Biacchesi S, Skiadopoulos MH, Boivin G, Hanson CT, Murphy BR, Collins PL, et al. Genetic diversity between human metapneumovirus subgroups. Virology. 2003;315(1):1-9.

[17] Papenburg J, Boivin G. The distinguishing features of human metapneumovirus and respiratory syncytial virus. Rev Med Virol. 2010;20(4):245-60.

[18] Principi N, Esposito S. Paediatric human metapneumovirus infection: epidemiology, prevention and therapy. J Clin Virol. 2014;59(3):141-7.

[19] Walsh EE, Peterson DR, Falsey AR. Human metapneumovirus infections in adults: another piece of the puzzle. Arch Intern Med. 2008;168(22):2489-96.

[20] Yang CF, Wang CK, Tollefson SJ, Piyaratna R, Lintao LD, Chu M, et al. Genetic diversity and evolution of human metapneumovirus fusion protein over twenty years. Sci Rep. 2015;5:15952.

[21] Esper F, Martinello RA, Boucher D, Weibel C, Ferguson D, Landry ML, et al. A 1-year experience with human metapneumovirus in children aged <5 years. J Infect Dis. 2004;189(8):1388-96.

[22] Boivin G, Abed Y, Pelletier G, Ruel L, Moisan D, Côté S, et al. Virological features and clinical manifestations associated with human metapneumovirus: a new paramyxovirus responsible for acute respiratory-tract infections in all age groups. J Infect Dis. 2002;186(9):1330-4.

[23] van den Hoogen BG, van Doornum GJ, Fockens JC, Cornelissen JJ, Beyer WE, de Groot R, et al. Prevalence and clinical symptoms of human metapneumovirus infection in hospitalized patients. J Infect Dis. 2003;188(10):1571-7.

[24] Williams JV, Edwards KM, Weinberg GA, Griffin MR, Hall CB, Zhu Y, et al. Population-based incidence of human metapneumovirus infection among hospitalized children. J Infect Dis. 2010;201(12):1890-8.

[25] Hamelin ME, Prince GA, Boivin G. Effect of ribavirin and glucocorticoid treatment in a mouse model of human metapneumovirus infection. Antimicrob Agents Chemother. 2006;50(2):774-7.

[26] Kahn JS, Kesebir D, Cotmore SF, D'Abramo A Jr, Cosby C, Weibel C, et al. Seroepidemiology of human bocavirus defined using recombinant virus-like particles. J Infect Dis. 2008;198(1):41-50.

[27] Bao X, Liu T, Shan Y, Li K, Garofalo RP, Casola A. Human metapneumovirus glycoprotein G inhibits innate immune responses. PLoS Pathog. 2008;4(5):e1000077.

[28] Melero JA, Mas V, McLellan JS. Structural, antigenic and immunogenic features of respiratory syncytial virus glycoproteins relevant for vaccine development. Vaccine. 2017;35(3):461-8.

[29] Wen SC, Williams JV. New approaches for immunization and therapy against human metapneumovirus. Clin Vaccine Immunol. 2015;22(8):858-66.

[30] Palavecino CE, Céspedes PF, Gómez RS, Kalergis AM, Bueno SM. Immunization with a recombinant bacillus Calmette-Guérin strain confers protective Th1 immunity against the human metapneumovirus. J Immunol. 2014;192(1):214-23.

[31] Hamelin ME, Couture C, Sackett MK, Boivin G. Enhanced lung disease and Th2 response following human metapneumovirus infection in mice immunized with the inactivated virus. J Gen Virol. 2007;88(12):3391-400.

[32] Darniot M, Pitoiset C, Petrella T, Aho S, Pothier P, Manoha C. Age-associated aggravation of clinical disease after primary metapneumovirus infection of BALB/c mice. J Virol. 2009;83(7):3323-32.

[33] Semple MG, Cowell A, Dove W, Greensill J, McNamara PS, Halfhide C, et al. Dual infection of infants by human metapneumovirus and human respiratory syncytial virus is strongly associated with severe bronchiolitis. J Infect Dis. 2005;191(3):382-6.

[34] Esper F, Boucher D, Weibel C, Martinello RA, Kahn JS. Human metapneumovirus infection in the United States: clinical manifestations associated with a newly emerging respiratory infection in children. Pediatrics. 2003;111(6):1407-10.

[35] Falsey AR, Walsh EE. Human metapneumovirus infection in adults. Pediatr Infect Dis J. 2008;27(10 Suppl):S80-3.

[36] Williams JV, Crowe JE Jr, Enriquez R, Minton P, Peebles RS Jr, Hamilton RG, et al. Human metapneumovirus infection plays an etiologic role in acute asthma exacerbations requiring hospitalization in adults. J Infect Dis. 2005;192(7):1149-53.

[37] Dokos C, Masjosthusmann K, Rellensmann G, Werner C, Schuler-Lüttmann S, Müller KM, et al. Fatal human metapneumovirus infection following allogeneic hematopoietic stem cell transplantation. Transpl Infect Dis. 2013;15(3):E97-101.

[38] Kahn JS, Psarras S, Papadopoulos NG. The pathophysiology of human metapneumovirus lower respiratory tract infection. Future Virol. 2010;5(2):163-73.

[39] Peiris JS, Tang WH, Chan KH, Khong PL, Guan Y, Lau YL, et al. Children with respiratory disease associated with metapneumovirus in Hong Kong. Emerg Infect Dis. 2003;9(6):628-33.

[40] Mackay IM, Bialasiewicz S, Jacob KC, McQueen E, Arden KE, Nissen MD, et al. Genetic diversity of human metapneumovirus over 4 consecutive years in Australia. J Infect Dis. 2006;193(12):1630-3.

[41] Kahn JS. Epidemiology of human metapneumovirus. Clin Microbiol Rev. 2006;19(3):546-57.

[42] Schildgen O, Müller A, Allander T, Mackay IM, Völz S, Kupfer B, et al. Human metapneumovirus: lessons learned over the first decade. Clin Microbiol Rev. 2011;24(4):734-54.

[43] Boivin G, De Serres G, Hamelin ME, Côté S, Argouin M, Tremblay G, et al. An outbreak of severe respiratory tract infection due to human metapneumovirus in a long-term care facility. Clin Infect Dis. 2007;44(9):1152-8.

[44] Bastien N, Liu L, Ward D, Taylor T, Li Y. Genetic variability of the G glycoprotein gene of human metapneumovirus. J Clin Microbiol. 2004;42(8):3532-7.

[45] Leung J, Esper F, Weibel C, Kahn JS. Seroepidemiology of human metapneumovirus (hMPV) on the basis of a novel enzyme-linked immunosorbent assay utilizing hMPV fusion protein expressed in recombinant vesicular stomatitis virus. J Clin Microbiol. 2005;43(3):1213-9.

[46] Edwards KM, Zhu Y, Griffin MR, Weinberg GA, Hall CB, Szilagyi PG, et al. New vaccine surveillance network. Burden of human metapneumovirus infection in young children. N Engl J Med. 2013;368(7):633-43.

[47] Schlapbach LJ, Agyeman P, Hutter D, Aebi C, Wagner BP, Riedel T. Human metapneumovirus infection as an emerging pathogen in pediatric respiratory distress syndrome. J Pediatr Intensive Care. 2011;2(1):11-6.

[48] Franklin D, Babl FE, Schlapbach LJ, Oakley E, Craig S, Neutze J, et al. A randomized trial of high-flow oxygen therapy in infants with bronchiolitis. N Engl J Med. 2018;378(12):1121-31.

[49] Pancham K, Sami I, Perez GF, Huseni S, Kurdi B, Rose MC, et al. Human metapneumovirus infection is associated with severe respiratory disease in preschool children with history of prematurity. Pediatrics. 2016;137(2):e20152387.

[50] Safdar A, Ramahi JM, Ohwada A, Raad II, Rolston KV. Fatal human metapneumovirus and influenza B virus coinfection in an allogeneic hematopoietic stem cell transplant recipient. Clin Infect Dis. 2007;44(9):e116-8.

[51] Wyde PR, Chetty SN, Jewell AM, Boivin G, Piedra PA. Comparison of the inhibition of human metapneumovirus and respiratory syncytial virus by ribavirin and immune serum globulin in vitro. Antiviral Res. 2003;60(1):51-9.

[52] Deffrasnes C, Hamelin ME, Prince GA, Boivin G. Identification and evaluation of a highly effective fusion inhibitor for human metapneumovirus. Antimicrob Agents Chemother. 2008;52(1):279-87.

[53] Ulbrandt ND, Ji H, Patel NK, Riggs JM, Brewah YA, Ready S, et al. Isolation and characterization of monoclonal antibodies which neutralize human metapneumovirus in vitro and in vivo. J Virol. 2006;80(16):7799-806.

[54] Siegel JD, Rhinehart E, Jackson M, Chiarello L; Healthcare Infection Control Practices Advisory Committee. 2007 Guideline for isolation precautions: preventing transmission of infectious agents in healthcare settings. Am J Infect Control. 2007;35(10 Suppl 2):S65-164.

[55] Lin CH, Wang YC, Lin YC, Liu CC, Chen YS, Tang RB, et al. The role of human metapneumovirus in children with acute respiratory infection in Taiwan. J Trop Pediatr. 2011;57(6):457-62.

[56] Buchholz UJ, Biacchesi S, Pham QN, Tran KC, Yang L, Luongo CL, et al. Deletion of M2 gene open reading frames 1 and 2 of human metapneumovirus: effects on RNA synthesis, attenuation, and immunogenicity. J Virol. 2005;79(11):6588-97.

[57] Battles MB, McLellan JS. Respiratory syncytial virus entry and how to block it. Nat Rev Microbiol. 2019;17(4):233-45.

[58] Ren J, Wang Q, Kolli D, Prusak DJ, Tseng CT, Chen ZY, et al. Human metapneumovirus M2-2 protein inhibits innate immune response in monocyte-derived dendritic cells. PLoS One. 2012;7(3):e34459.

[59] Cox RG, Erickson JJ, Hastings AK, Becker JC, Johnson M, Craven RE, et al. Human metapneumovirus virus-like particles induce protective B and T cell responses in a mouse model. J Virol. 2014;88(11):6368-79.

[60] Lévy C, Aerts L, Hamelin ME, Granier C, Szécsi J, Lavillette D, et al. Virus-like particle vaccine induces cross-protection against human metapneumovirus infections in mice. Vaccine. 2013;31(25):2778-85

[61] Corti D, Bianchi S, Vanzetta F, Minola A, Perez L, Agatic G, et al. Cross-neutralization of four paramyxoviruses by a human monoclonal antibody. Nature. 2013;501(7467):439-43.

[62] Palavecino CE, Cespedes PF, Gomez RS, Kalergis AM, Bueno SM. Immunization with a recombinant bacillus Calmette-Guerin strain confers protective Th1 immunity against the human metapneumovirus. J Immunol. 2014;192(1):214-23.

[63] Hastings AK, Erickson JJ, Schuster JE, Boyd KL, Tollefson SJ, Johnson M, et al. Role of type I interferon signaling in human metapneumovirus infection of dendritic cells. J Virol. 2015;89(18):9831-41.

[64] Goutagny N, Jiang Z, Tian J, Parroche P, Schickli J, Monks BG, et al. Cell type-specific recognition of human metapneumoviruses (HMPVs) by retinoic acid-inducible gene I (RIG-I) and TLR7 and viral interference of RIG-I ligand recognition by HMPV-B1 phosphoprotein. J Immunol. 2010;184(3):1168-79.

[65] Bao X, Kolli D, Liu T, Shan Y, Garofalo RP, Casola A. Human metapneumovirus small hydrophobic protein inhibits NF-κB transcriptional activity. J Virol. 2008;82(16):8224-9.

[66] Yang Z, Ren J, Ye J, Chen X, Jiang X, Zhang S, et al. Structural basis of human metapneumovirus neutralization by a potent monoclonal antibody targeting the fusion glycoprotein. Nat Commun. 2021;12(1):6646